Journal
MOLECULAR PHARMACEUTICS
Volume 18, Issue 2, Pages 576-592Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.molpharmaceut.0c00383
Keywords
influenza; vaccine; nanoparticles; particles; antigens
Funding
- National Institutes of Health [R01AI148557, R21AI122964, DP5OD017898]
Ask authors/readers for more resources
The combination of recombinant biotechnology and nanomedicine techniques shows promise in developing a next-generation flu vaccine with broad protection. Various nanoparticle candidates have been tested, showing protection against different influenza strains, production of antibodies with broad reactivity, and activation of potent T cell responses. The future of influenza vaccines may involve combining recombinant antigens with nanoparticle carriers.
Influenza viruses cause seasonal epidemics and represent a pandemic risk. With current vaccine methods struggling to protect populations against emerging strains, there is a demand for a next-generation flu vaccine capable of providing broad protection. Recombinant biotechnology, combined with nanomedicine techniques, could address this demand by increasing immunogenicity and directing immune responses toward conserved antigenic targets on the virus. Various nanoparticle candidates have been tested for use in vaccines, including virus-like particles, protein and carbohydrate nanoconstructs, antigen-carrying lipid particles, and synthetic and inorganic particles modified for antigen presentation. These methods have yielded some promising results, including protection in animal models against antigenically distinct influenza strains, production of antibodies with broad reactivity, and activation of potent T cell responses. Based on the evidence of current research, it is feasible that the next generation of influenza vaccines will combine recombinant antigens with nanoparticle carriers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available